Pharma batch and investigation benefit estimator
Explore the cost of rejected batches and investigation effort
Keep batch-loss reduction and time released from investigations separate so your business case remains reviewable.
BUILD YOUR SCENARIO
Enter your own baseline
Your entries stay in this browser tab. They are not sent to NeoBram or included in analytics. Reloading or closing the tab clears them. Printing or copying creates a copy under your control; the contact form does not receive your entries.
Use one currency throughout. Changing the currency changes the unit label only; it does not convert any amount.
Record the non-confidential boundary for this estimate so printed scenarios remain understandable.
Base scenario
Choose a cost-only, capacity-only or separate two-part view.
Add costs only when you have a supportable cash-benefit estimate.
What your assumptions imply
Enter your baseline and an improvement assumption to calculate a scenario.
How this is calculated
- Baseline rejected batchesBatches produced per year * Measured rejected-batch rate / 100
- Potential rejected batches avoidedBaseline rejected batches * Assumed relative rejection reduction / 100
- Gross avoided batch-loss costPotential rejected batches avoided * Avoidable cost per rejected batch
- Net investigation capacity releasedInvestigations per year * Net hours released per investigation
- Indicative investigation capacity valueNet investigation capacity released * Loaded investigator hourly cost
Costs and cash realization
- Annual net operating cash benefitRealizable annual cash benefit - Annual recurring operating cost
- First-year net cash benefitRealizable annual cash benefit - Annual recurring operating cost - One-time implementation investment
- Simple payback at full stated annual benefit12 * One-time implementation investment / Annual net operating cash benefit
- First-year undiscounted ROI at full stated annual benefit100 * First-year net cash benefit / (One-time implementation investment + Annual recurring operating cost)
Illustrative scenario only. This is not a quote, forecast, guarantee or verified customer outcome. Confirm the baseline, avoid overlapping benefits and include delivery and operating costs before approving investment.
Keep this estimate with your readiness worksheet or evidence record. For each scenario, record the source/reference, measured period and owner role; mark measured inputs versus assumptions, uncertainty or ranges, and unresolved questions. Copy or print both records before leaving their pages; entries are not carried between pages. Start an enquiry with a non-confidential description only. Open the readiness worksheet.
Scenario record
Pharma batch and investigation benefit estimator Workflow or asset scope: Not entered Currency: Not selected Illustrative scenario only. This is not a quote, forecast, guarantee or verified customer outcome. Confirm the baseline, avoid overlapping benefits and include delivery and operating costs before approving investment. Your entries stay in this browser tab. They are not sent to NeoBram or included in analytics. Reloading or closing the tab clears them. Printing or copying creates a copy under your control; the contact form does not receive your entries. Keep this estimate with your readiness worksheet or evidence record. For each scenario, record the source/reference, measured period and owner role; mark measured inputs versus assumptions, uncertainty or ranges, and unresolved questions. Copy or print both records before leaving their pages; entries are not carried between pages. Start an enquiry with a non-confidential description only. Base scenario What would you like to estimate?: Not entered Complete the required fields. No estimate has been calculated yet. How this is calculated baseline_rejected_batches = annual_batches * rejection_rate_percent / 100 expected_avoided_rejections = baseline_rejected_batches * rejection_reduction_percent / 100 gross_avoided_batch_loss_cost = expected_avoided_rejections * avoidable_batch_cost investigation_hours_released = annual_investigations * hours_per_investigation investigation_capacity_value = investigation_hours_released * investigator_hourly_cost
Define the quality outcome precisely
Enter rejected batches, not every deviation or investigation. The causes that AI-assisted work could influence must be identified before assigning a reduction assumption. Faster access to quality records may help investigation without directly preventing batch rejection. Model that benefit separately when causality has not been established.
Use an approved avoidable batch cost
Batch selling price can overstate a loss, especially when material can be recovered or production rescheduled. Work with finance and quality to choose an incremental cost that fits the scenario. Do not include regulatory penalties, audit outcomes or reputational effects as automatic benefits.
Count investigation capacity honestly
Net hours released should include source verification, review and record-completion effort. Value that time as capacity unless an actual spending change is approved. Add validation, controlled integration, infrastructure, licences and ongoing operation before an investment decision. The estimator does not establish suitability for a regulated intended use.
About this estimate
Illustrative scenario only. This is not a quote, forecast, guarantee or verified customer outcome. Confirm the baseline, avoid overlapping benefits and include delivery and operating costs before approving investment.
Your entries stay in this browser tab. They are not sent to NeoBram or included in analytics. Reloading or closing the tab clears them. Printing or copying creates a copy under your control; the contact form does not receive your entries.
More clarity
Questions and answers
Does faster CAPA closure prove fewer rejected batches?
No. These are different outcomes and need separate measurements and evidence.
Does the estimate assume regulatory compliance?
No. Intended use, validation and applicable requirements must be assessed for the specific implementation.
Does this result include project costs?
The main result is a gross scenario. The optional cash-based investment view uses your separate realizable cash-benefit estimate and deducts implementation and operating costs. It does not automatically turn capacity or exposure into cash savings.
Are my inputs sent to NeoBram?
No. Calculation runs in your browser tab. Your entries are not sent through analytics or passed to the contact form. You can choose to print or copy a summary yourself.
Start with one business problem